AstraZeneca bets on gene editing for broad range of new drugs

Tuesday, 24 February 2015 00:44 - - {{hitsCtrl.values.hits}}

Four research deals tap into pioneering CRISPR technology AstraZeneca working with academic groups and Thermo Fisher Builds on in-house CRISPR program at drugmaker LONDON (Reuters): AstraZeneca said recently it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases. The academic and commercial tie-ups will allow British-based AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine. CRISPR, which stands for clustered regularly interspaced short palindromic repeats, allows scientists to edit the genes of selected cells accurately and efficiently. It has created excitement since emerging two years ago and is already being tipped for a Nobel Prize. The collaborations with Britain’s Wellcome Trust Sanger Institute, the Innovative Genomics Initiative in California, the Broad Institute and Whitehead Institute in Massachusetts, and Thermo Fisher Scientific build on an in-house CRISPR programme at AstraZeneca that has been running for over a year. Other drugmakers, keen to exploit the potential of a powerful new scientific tool, are also jumping on the bandwagon. Earlier this month Switzerland’s Novartis struck deals with Intellia Therapeutics and Caribou Biosciences, two unlisted US biotech companies that have been set up to take advantage of CRISPR. While certain existing techniques already allow scientists to add genes to cells, CRISPR lets them make changes in specific genes far faster and in a much more precise way. It is also much easier to handle in the laboratory. AstraZeneca believes the technology will help it identify and validate new drug targets more quickly, accelerating the drug development process. “CRISPR is a simple yet powerful tool that enables us to manipulate genes of potential importance in disease pathways and examine the impact of these modifications in a highly precise way,” said Mene Pangalos, AstraZeneca’s head of innovative medicines and early development. No financial details of the collaborations were disclosed but AstraZeneca said it would share cell lines and compounds with its partners, based on an ‘open innovation’ research model. Neither side will own any targets identified.